Thalomid Oncology Use Is Proof Of Anti-Angiogenic Drug Concept - EntreMed
Executive Summary
Extensive off-label use of Celgene's Thalomid (thalidomide) in oncology is demonstrating the clinical principle of anti-angiogenic drug therapy in actual practice, EntreMed President John Holaday maintained during an April 8 presentation at the Wharton New Ventures in Health Care Conference in Philadelphia.